Follow us on:

ECO Animal Health Group CEO David Hallas Delivering a Strong Set of Results (VIDEO)

ECO Animal Health Group plc (LON:EAH) CEO David Hallas joins DirectorsTalk to discuss results for the six months ended 30 September 2023.

David talks us through the highlights, the growth in revenues for China, Japan, USA & Canada, the improved cash position, what the approval of Aivlosin® from the US FDA and Veterinary Drugs Directorate in Canada means for the company, the markets and impact on ECO and the outlook for the company and its R&D pipeline.

ECO Animal Health Group plc is a leader in the development, registration and marketing of pharmaceutical products for global animal health markets.

Find more news, interviews, share price & company profile here for:Eco Animal Health Group plc

Share this interview

Other Interviews

More News

ECO Animal Health Group revenue ahead of market expectations July 10, 2023
ECO Animal Health Group experienced strong trading Q4 as demand increases March 23, 2023
ECO Animal Health participating at Animal Health, Nutrition and Technology Innovation summit March 8, 2023
ECO Animal Health Group in line with full year expectations November 23, 2022
ECO Animal Health investor presentation covering interim results November 22, 2022
ECO Animal Health Group appoint Haysmacintyre LLP as auditor November 14, 2022
ECO Animal Health annual report and accounts & AGM September 2, 2022
ECO Animal Health Group pleased with new bank facility agreement July 11, 2022
ECO Animal Health Group partners with UK Moredun Research Institute July 6, 2022
ECO Animal Health enters into research partners with Imperial College London June 15, 2022

Search

Useful links

Disclaimer

You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular stock, share, security, portfolio of securities, transaction, investment strategy, or other matter. We openly disclose that we and our contributors may have interests in investments and/or providers of services referred to within the website and that we receive remuneration from certain of the companies referred to on this website.

© 2024 – DirectorsTalk Interviews. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.